阿替利珠单抗联合铂类双药化疗治疗晚期非小细胞肺癌的长期生存随访
联合方案耐受良好,ORR为36%-68%,中位PFS 5.7-8.4个月,中位OS 12.9-18.9个月,但样本量小限制分析。
要点
- 阿替利珠单抗联合铂类双药化疗一线治疗晚期NSCLC耐受良好。
- 确认ORR:紫杉醇组36%,培美曲塞组68%,白蛋白紫杉醇组46%。
- 中位OS:紫杉醇组12.9个月,培美曲塞组18.9个月,白蛋白紫杉醇组17.0个月。
核心结论
- 阿替利珠单抗联合化疗耐受良好且疗效令人鼓舞,但分析受样本量小限制。
主要发现
- 常见治疗相关III/IV级不良事件为中性粒细胞减少(C组36%、D组36%、E组42%)和贫血(C组16%、D组16%、E组31%)。
- 确认ORR:C组36%,D组68%(1例完全缓解),E组46%(4例完全缓解)。
- 中位PFS:C组7.1个月(95%CI 4.2-8.3),D组8.4个月(95%CI 4.7-11),E组5.7个月(95%CI 4.4-14.8)。
- 中位OS:C组12.9个月(95%CI 8.8-21.3),D组18.9个月(95%CI 9.9-27.4),E组17.0个月(95%CI 12.7-不可评估)。
临床怎么用
- 阿替利珠单抗联合铂类双药化疗可作为晚期NSCLC一线治疗选择之一,但需注意样本量小,结果需进一步研究验证。
局限性
- 分析受样本量小限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Before the availability of immunotherapy, chemotherapy was standard first-line therapy for non-small-cell lung cancer (NSCLC) lacking actionable gene alterations. Preclinical evidence suggests chemotherapy is immunomodulatory, supporting chemotherapy/immunotherapy combinations. Atezolizumab, anti-programmed death ligand-1 (PD-L1) antibody, blocks programmed cell death protein-1 and B7.1 interaction with PD-L1. GP28328 (NCT01633970) assessed atezolizumab with chemotherapy in multiple tumours; we report results for advanced, treatment-naïve NSCLC. METHODS: Patients received atezolizumab plus carboplatin with paclitaxel (Arm C: atezo/cb/pac), pemetrexed (Arm D: atezo/cb/pem, maintenance pemetrexed permitted), or nab-paclitaxel (Arm E: atezo/cb/nab-pac), four-six cycles, then atezolizumab maintenance. Primary end-point was safety; secondary end-points were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: Seventy-six NSCLC patients were enrolled (n = 25, 25 and 26 for Arms C, D and E, respectively). Common treatment-related grade III/IV adverse events were neutropenia (36% atezo/cb/pac, 36% atezo/cb/pem, 42% atezo/cb/nab-pac) and anaemia (16% atezo/cb/pac, 16% atezo/cb/pem, 31% atezo/cb/nab-pac). Confirmed ORRs were 36% atezo/cb/pac, 68% atezo/cb/pem (one complete response [CR]) and 46% atezo/cb/nab-pac (four CRs). Median PFS was 7.1 months, (95% confidence interval [CI]: 4.2-8.3), 8.4 months (95% CI: 4.7-11) and 5.7 months (95% CI: 4.4-14.8), respectively. Median OS was 12.9 months (95% CI: 8.8-21.3), 18.9 months (95% CI: 9.9-27.4) and 17.0 months (95% CI: 12.7-not evaluable), respectively. CONCLUSION: Atezolizumab with chemotherapy was well tolerated with encouraging efficacy, though the analysis was limited by small numbers. NSCLC chemotherapy combination studies are ongoing. CLINICALTRIALS. GOV IDENTIFIER: NCT01633970.
引用
- Liu SV, Camidge DR, Gettinger SN, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018. PMID: 30053670. doi:10.1016/j.ejca.2018.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。